Login / Signup

A child with semaphorin 3b-associated membranous nephropathy effectively treated with obinutuzumab after rituximab resistance.

Ester ConversanoHanna DebiecManuela ColucciFrancesco EmmaPierre RoncoMarina Vivarelli
Published in: Pediatric nephrology (Berlin, Germany) (2023)
Obinutuzumab was safe and well-tolerated, and may therefore represent an effective therapeutic alternative in children with primary MN and rituximab resistance.
Keyphrases
  • chronic lymphocytic leukemia
  • diffuse large b cell lymphoma
  • young adults
  • hodgkin lymphoma
  • mental health
  • ionic liquid